Pacira to Report 2025 Financial Results on Thursday February 26, 2026

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

GlobeNewsWire • Feb 12, 2026

Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction (“NOPAIN”) Act.

GlobeNewsWire • Feb 12, 2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company.

GlobeNewsWire • Feb 9, 2026

Pacira BioSciences: Mispriced On Generic Risks That Are Years Away

Pacira BioSciences trades at distressed levels due to fears of EXPAREL patent erosion, despite strong cash flow and 78% gross margins. EXPAREL's manufacturing complexity and hospital adoption create a significant moat, making immediate generic substitution unlikely even after patent setbacks. The NOPAIN Act introduces a major reimbursement tailwind, shifting EXPAREL from a hospital cost burden to a neutral or positive economic choice.

Seeking Alpha • Feb 9, 2026

5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates

Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.

Zacks Investment Research • Feb 3, 2026

Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D.

GlobeNewsWire • Jan 28, 2026

Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Jan 27, 2026

Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why

Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research • Jan 27, 2026

Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific

Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels to support international growth.

Zacks Investment Research • Jan 14, 2026